Delivering Breakthrough


About Us

MyMD Pharmaceuticals, Inc., is a closely held company that is committed to developing and commercializing potentially potent small molecules that we believe offer significant therapeutic promise, particularly in devastating diseases such as cancers and various autoimmune disorders.


Through our commitment to patients suffering from devastating diseases, MyMD is developing a platform of potential products based on our proprietary small molecule.

MyMD’s early stage development program emphasizes collaboration with a team of highly experienced professionals and CROs. We believe that our collaborative strategy supports cost-effective product innovation and accelerated drug development.

The company has developed a small molecule for which we believe will have a beneficial effect on Reactive Oxygen Species through modulation of Hydrogen Peroxide. Recent scientific findings have implicated a strong relationship between ROS accumulation and the initiation and progression of autoimmunity.

Reactive oxygen species in organ-specific autoimmunity.

Di Dalmazi G1,2, Hirshberg J3, Lyle D3, Freij JB4, Caturegli P5,6. Auto Immun Highlights.2016 Dec;7(1):11. doi: 10.1007/s13317-016-0083-0.

We are happy to answer any questions you may have about our company and for our exciting, breakthrough therapeutics. We are open to expressions of interest with respect to partnership at all stages of development. For more information, please fill out the form below and we will be in touch with you shortly.


324 South Hyde Park Ave Suite 350, Tampa, FL 33606